ClinicalTrials.gg
CompletedNCT03873740Updated Jul 29, 2021

Immunogenicity and Safety of Two Different Commercial EV71 Vaccines

A Phase 4 interventional study of EV71 inactived vaccine(Vero cells) and EV71 inactived vaccine(Human diploid cells) in Hand, Foot and Mouth Disease, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 6 Months to 35 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-29.

Sponsored by Sinovac Biotech Co., Ltd · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2018, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
6 Months to 35 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd — 4 open to participants now, 4 under way, 2 of them phase 3. Hand, Foot and Mouth Disease · Sinovac Biotech Co., Ltd.

Enrollment
13th of 15
300 · median 744
Started
2018
the only one that year
Phase 4
6 of 20
none open now
Registered
8th of 20
by date

Among the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 4, and was the 8th registered.

Hand, Foot and Mouth Disease

59 studies on the registry are indexed under Hand, Foot and Mouth Disease; 10 are open to participants now.

Browse Hand, Foot and Mouth Disease studies →

Open to participants now

4 of the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 4 Hand, Foot and Mouth Disease studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 6 Months to 35 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months.

Read the detailed description

This study is a opened,randomized and controlled phase Ⅳ clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months. EV71 inactived vaccines(Vero cells)was manufactured by Sinovac Biotech Co., Ltd and EV71 inactived vaccines(Human diploid cells)was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.300 infants aged between 6-35 months will be randomly assigned into experimental group in the ratio 1:1:1:1.The experimental group 1 received two doses EV71 inactived vaccines(Vero cells)on day 0 and 30. The experimental group 2 received two doses EV71 inactived vaccines (Human diploid cells)on day 0 and 30. The experimental group 3 received one dose EV71 inactived vaccines (Vero cells)on day 0 and one dose EV71 inactived vaccines (Human diploid cells)on day 30.The experimental group 4 received one dose EV71 inactived vaccines (Human diploid cells)on day 0 and one dose EV71 inactived vaccines (Vero cells)on day 30. To evaluate the immunogenicity of the vaccine, venous blood will be collected for the EV71 neutralizing antibody detection prior to vaccination and 30 days after the 2nd dose vaccination.

03

Conditions studied

  • Hand, Foot and Mouth Disease

Keywords

  • Inactivated Enterovirus Type 71 (EV71) Vaccine
  • Sequential vaccination
  • Immunity
  • Safety
04

Who can participate

Ages eligible
6 Months to 35 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteer aged 6-35 months;
  • Proven legal identity;
  • Guardians of the participants should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study.

Exclusion criteria

Exclusion Criteria:

  • Prior vaccination with EV71 vaccine;
  • History of hand,foot and mouth disease;
  • Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria,difficulty in breathing, angioneurotic edema, pain, etc;
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
  • diseases or immunodeficiency/;
  • Severe neurological disorders (epilepsy, convulsions or convulsions) or psychosis;
  • History of thyroidectomy, absence of spleen, functional absence of spleen, and any circumstances leading to absence of spleen or splenectomy;
  • Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or abnormalities) , or obvious bruising or coagulation disorders;
  • Any immunosuppressant, cytotoxic medicine, or inhaled (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months;
  • Receipt of any of the following products:

    1. Blood product within 3 months prior to study entry;
    2. Any within 14 days prior to study entry;
    3. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
    4. Any other study drugs within 30 days prior to study entry;
  • Acute disease or acute stage of chronic disease within 7 days prior to study entry;
  • Axillary temperature > 37.0℃;
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Single vaccine group A

    This group receive two doses injection of EV71 inactived vaccines(Vero cells) on Day 0 and 30, and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.

    Biological: EV71 inactived vaccine(Vero cells)

  • Experimental
    Single vaccine group B

    This group receive two doses injection of EV71 inactived vaccines(human diploid cells)on Day 0 and 30, two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.

    Biological: EV71 inactived vaccine(Human diploid cells)

  • Experimental
    Sequential vaccination group A

    One dose injection of EV71 inactived vaccines(Vero cells) on Day 0,following one dose of EV71 vaccine(EV71 inactived vaccines(human diploid cells), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.

    Biological: EV71 inactived vaccine(Vero cells) · Biological: EV71 inactived vaccine(Human diploid cells)

  • Experimental
    Sequential vaccination group B

    One dose injection of EV71 inactived vaccines(human diploid cells)on Day 0,following one does of EV71 vaccine(Sinovac Vaccine Technology Co., Ltd), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.

    Biological: EV71 inactived vaccine(Vero cells) · Biological: EV71 inactived vaccine(Human diploid cells)

Interventions

06

What researchers measure

Primary outcomes

  1. The seroconversion rates (SCR) of the EV71 neutralizing antibody calculated based on the cutoff value of 1:8.

    Subjects whose pre-immune EV71 antibody level \< 1:8 and post-immune antibody level ≥ 1:8, or those whose pre-immune antibody level ≥ 1:8 and the increase of post-immune EV71 antibody level ≥ 4 folds are considered seroconverted

    Time frame: 30 days after two doses

Secondary outcomes

  1. The incidences of adverse reactions after each does

    After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. Unsolicited adverse events on day 0-30 were also reported. Each AE case will be reviewed by the investigator to determine whether or not it was an adverse reaction (The vaccination-related AE).

    Time frame: 0-30 days after each dose

  2. The incidence of solicited local and general adverse events after each does

    After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. Each AE case will be reviewed by the investigator to determine whether or not it was an adverse reaction (The vaccination-related AE).

    Time frame: 0-7 days after each dose

  3. Incidence of serious adverse events (SAEs) during the period of safety monitoring

    Serious adverse events (SAEs) will be collected during the period of safety monitoring after each dose.

    Time frame: 0-30 days after each dose

  4. EV71 neutralizing antibody positive rate of each group after two doses.

    Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive.

    Time frame: 30 days after two doses

  5. The Geometric mean titer (GMT) of the EV71 neutralizing antibody

    The GMT 30 days of each group after two doses.

    Time frame: 30 days after two doses

  6. The geometric mean fold increase (GMI) of the EV71 neutralizing antibody

    The GMI 30 days of each group after two doses.

    Time frame: 30 days after two doses

07

Study locations

1 site
  • Rushan City Center for Disease Control and Prevention
    Rushan, Shandong 264500, China
08

References and documents

Publications

  • Xu Q, Cao Q, Yang W, Liu X, Liu H, Tian X, Li J, Fang X, Jia N, Zeng G, Xu A. Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial. Vaccine. 2020 Mar 10;38(12):2671-2677. doi: 10.1016/j.vaccine.2020.02.013. Epub 2020 Feb 14. PubMed 32067817 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Jan 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2019
First posted
Mar 13, 2019
StartActual
Nov 6, 2018
Primary completionActual
Jan 21, 2019
CompletionActual
Jan 23, 2019
Last update
Jul 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03873740
Collaborators
Shandong Province Centers for Disease Control and Prevention
Responsible party
Sponsor
First posted
Mar 13, 2019
Start date
Nov 6, 2018
Primary completion
Jan 21, 2019
Completion
Jan 23, 2019
Last update
Jul 29, 2021

Study contacts

AIqiang Xu
principal investigator · Shandong Provincal Center for Disease Control and Preventione

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EV71

Start the discussion